Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies

被引：100

作者：

Shojaei, Farbod ^{[1
]}

Ferrara, Napoleone ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

DRUG RESISTANCE UPDATES | 2008年 / 11卷 / 06期

关键词：

Tumor angiogenesis; VEGF; Anti-VEGF; Stromal cells; CD11b+Gr1+cells; Tumor-associated endothelial cells; Endothelial progenitor cells;

D O I：

10.1016/j.drup.2008.09.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Angiogenesis is critical for growth of many tumor types and the development of anti-angiogenic agents opened a new era in cancer therapy. However, similar to other anti-cancer therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in cancer patients leading to disease recurrence. Recent studies in several experimental models suggest that both tumor and non-tumor (stromal) cell types may be involved in the reduced responsiveness to the treatments. The current review focuses on the role of stromal cells in tumor growth and in refractoriness to anti-VEGF treatment. (C) 2008 Elsevier Ltd. All rights reserved.

引用

收藏

页码：219 / 230

页数：12

相关论文

共 175 条

[41] The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

[42] The biology of vascular endothelial growth factor [J].

Ferrara, N ;

DavisSmyth, T .

ENDOCRINE REVIEWS, 1997, 18 (01) :4-25

[43] Angiogenesis as a therapeutic target [J].

Ferrara, N ;

Kerbel, RS .

NATURE, 2005, 438 (7070) :967-974

[44] Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine [J].

Filipazzi, Paola ;

Valenti, Roberta ;

Huber, Veronica ;

Pilla, Lorenzo ;

Canese, Paola ;

Iero, Manuela ;

Castelli, Chiara ;

Mariani, Luigi ;

Parmiani, Giorgio ;

Rivoltini, Licia .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2546-2553

[45] Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels [J].

Fischer, Christian ;

Jonckx, Bart ;

Mazzone, Massimiliano ;

Zacchigna, Serena ;

Loges, Sonja ;

Pattarini, Lucia ;

Chorianopoulos, Emmanuel ;

Liesenborghs, Laurens ;

Koch, Marta ;

De Mol, Maria ;

Autiero, Monica ;

Wyns, Sabine ;

Plaisance, Stephane ;

Moons, Lieve ;

van Rooijen, Nico ;

Giacca, Mauro ;

Stassen, Jean-Marie ;

Dewerchin, Mieke ;

Collen, Desire ;

Carmeliet, Peter .

CELL, 2007, 131 (03) :463-475

[46] Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs [J].

Fojo, Tito .

DRUG RESISTANCE UPDATES, 2007, 10 (1-2) :59-67

[47] Endogenous angiogenesis inhibitors [J].

Folkman, J .

APMIS, 2004, 112 (7-8) :496-507

[48]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[49] Opinion - Angiogenesis: an organizing principle for drug discovery? [J].

Folkman, Judah .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (04) :273-286

[50] Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [J].

Gabrilovich, DI ;

Chen, HL ;

Cunningham, HT ;

Meny, GM ;

Nadaf, S ;

Kavanaugh, D ;

Carbone, DP .

NATURE MEDICINE, 1996, 2 (10) :1096-1103

← 1 2 3 4 5 6 7 8 9 10 →